Pfizer Inc.laid out a timetable for reaching key milestones in the development of its Covid-19 vaccine that could mean the shots start becoming available in the U.S. before year\u2019s end.<\/p>\n
Chief Executive Albert Bourla said Friday the company could start to see from a large study whether the vaccine works by the end of this month and would have data on its safety by the third week of November. If the preliminary results indicate the vaccine can work safely, Pfizer could ask U.S. health regulators to permit use by late November, Mr. Bourla said.<\/p>\n
The timetable, which Mr. Bourla provided in a letter posted to Pfizer\u2019s website, suggests the shots could start going into use in late November, or more likely in December, since regulators would probably need some time to review the study data as well as Pfizer\u2019s manufacturing operations.<\/p>\n
New York-based Pfizer is developing its vaccine candidate with German partner BioNTech SE.<\/p>\n
It is far from certain the vaccine would prove to work safely in the trial now enrolling some 44,000 volunteers. And the timetable could be pushed back for a number of reasons, including if it takes longer than Pfizer expects for study subjects to get exposed to the virus.<\/p>\n
Read it all<\/a>.<\/p>\n Drug giant Pfizer said it could be ready to apply for emergency-use authorization of its Covid-19 vaccine by late November, assuming it receives positive efficacy and safety data from late-stage human trials https:\/\/t.co\/qrffJBBO7S<\/a><\/p>\n — The Wall Street Journal (@WSJ) October 16, 2020<\/a><\/p><\/blockquote>\n \n